Actively Recruiting
Endoscopic Retrograde Cholangiopancreatography
Led by Methodist Health System · Updated on 2026-03-24
100
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis) are of great importance.
CONDITIONS
Official Title
Endoscopic Retrograde Cholangiopancreatography
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients older than 15 years
- Underwent ERCP between January 1, 2000, and December 31, 2025
- Included in Methodist Dallas Medical Center's registry
You will not qualify if you...
- Patients younger than 15 years
- Cannulation performed via a surgical anastomosis
- Cannulation not attempted due to gastric outlet obstruction
- Main papilla not found
- Minor papilla not found
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Methodist Dallas Medical Center- Clinical Research Institute
Dallas, Texas, United States, 75203
Actively Recruiting
Research Team
C
Crystee Cooper, DHEd
CONTACT
K
Kavya Mankulangara
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here